Clinical trial
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in…
NCT00412789 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00412789 |
|---|---|
| Title | Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan |
| Official title | A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Patupilone |
| Enrollment | 15 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2008 |
| First posted | Dec 18, 2006 |
| Last update posted | May 31, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: